Clinical theragnostic potential of diverse mirna expressions in prostate cancer: A systematic review and meta-analysis

Rama Jayaraj, Greg Raymond, Sunil Krishnan, Katherine S. Tzou, Siddhartha Baxi, M. Ravishankar Ram, Suresh Kumar Govind, Harish C. Chandramoorthy, Faisal N. Abu-Khzam, Peter Shaw

Research output: Contribution to journalArticle

Abstract

Background: Prostate cancer (PrC) is the second-most frequent cancer in men, its incidence is emerging globally and is the fifth leading cause of death worldwide. While diagnosis and prognosis of PrC have been studied well, the associated therapeutic biomarkers have not yet been investigated comprehensively. This systematic review and meta-analysis aim to evaluate the theragnostic effects of microRNA expressions on chemoresistance in prostate cancer and to analyse the utility of miRNAs as clinical theragnostic biomarkers. Methods: A systematic literature search for studies reporting miRNA expressions and their role in chemoresistance in PrC published until 2018 was collected from bibliographic databases. The evaluation of data was performed as per PRISMA guidelines for systematic review and meta-analysis. Meta-analysis was performed using a random-effects model using Comprehensive Meta-Analysis (CMA) software. Heterogeneity between studies was analysed using Cochran’s Q test, I2 and the Tau statistic. Quality assessment of the studies was performed using the Newcastle–Ottawa Scale (NOS) for the methodological assessment of cohort studies. Publication bias was assessed using Egger’s bias indicator test, Orwin and classic fail-safe N test, Begg and Mazumdar rank collection test, and Duval and Tweedie’s trim and fill methods. Findings: Out of 2909 studies retrieved, 79 studies were shortlisted and reviewed. A total of 17 studies met our eligibility criteria, from which 779 PrC patients and 17 chemotherapy drugs were examined, including docetaxel and paclitaxel. The majority of the drug regulatory genes reported were involved in cell survival, angiogenesis and cell proliferation pathways. We studied 42 miRNAs across all studies, out of which two miRNAs were found to be influencing chemosensitivity, while 21 were involved in chemoresistance. However, the remaining 19 miRNAs did not appear to have any theragnostic effects. Besides, the prognostic impact of the miRNAs was evaluated and had a pooled HR value of 1.960 with 95% CI (1.377–2.791). Interpretation: The observation of the current study depicts the significance of miRNA expression as a theragnostic biomarker in medical oncology. This review suggests the involvement of specific miRNAs as predictors of chemoresistance and sensitivity in PrC. Hence, the current systematic review and meta-analysis provide insight on the use of miRNA as PrC biomarkers, which can be harnessed as molecular candidates for therapeutic targeting.

Original languageEnglish
Article number1199
JournalCancers
Volume12
Issue number5
DOIs
Publication statusPublished - May 2020

Fingerprint Dive into the research topics of 'Clinical theragnostic potential of diverse mirna expressions in prostate cancer: A systematic review and meta-analysis'. Together they form a unique fingerprint.

  • Cite this

    Jayaraj, R., Raymond, G., Krishnan, S., Tzou, K. S., Baxi, S., Ram, M. R., Govind, S. K., Chandramoorthy, H. C., Abu-Khzam, F. N., & Shaw, P. (2020). Clinical theragnostic potential of diverse mirna expressions in prostate cancer: A systematic review and meta-analysis. Cancers, 12(5), [1199]. https://doi.org/10.3390/cancers12051199